HC Wainwright Raises Earnings Estimates for BridgeBio Pharma

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings estimates for BridgeBio Pharma in a research note issued to investors on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.51) per share for the quarter, up from their previous forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($1.69) EPS.

A number of other brokerages have also commented on BBIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Pharma in a research report on Wednesday, January 21st. Piper Sandler raised their target price on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Raymond James Financial set a $89.00 price target on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a research note on Thursday, February 12th. The Goldman Sachs Group increased their price objective on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Wells Fargo & Company lifted their target price on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $82.05.

BridgeBio Pharma Stock Performance

Shares of BBIO opened at $68.14 on Thursday. The business’s fifty day moving average price is $75.52 and its two-hundred day moving average price is $63.98. The firm has a market capitalization of $13.13 billion, a price-to-earnings ratio of -16.30 and a beta of 1.13. BridgeBio Pharma has a 52 week low of $28.33 and a 52 week high of $84.94.

Insider Activity

In other news, Director Randal W. Scott sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total value of $754,600.00. Following the completion of the transaction, the director owned 11,589 shares of the company’s stock, valued at $874,505.94. The trade was a 46.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $74.26, for a total value of $148,520.00. Following the sale, the chief accounting officer directly owned 130,297 shares in the company, valued at $9,675,855.22. The trade was a 1.51% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 176,121 shares of company stock valued at $13,009,631. 18.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On BridgeBio Pharma

A number of hedge funds have recently modified their holdings of the business. Brooklands Fund Management Ltd acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at approximately $210,348,000. Price T Rowe Associates Inc. MD lifted its stake in BridgeBio Pharma by 144.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock valued at $292,862,000 after buying an additional 2,261,181 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in shares of BridgeBio Pharma by 25.8% in the fourth quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock valued at $841,349,000 after buying an additional 2,259,378 shares during the period. Norges Bank bought a new stake in shares of BridgeBio Pharma during the second quarter worth $84,488,000. Finally, Wellington Management Group LLP increased its position in shares of BridgeBio Pharma by 130.4% during the fourth quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company’s stock worth $179,654,000 after acquiring an additional 1,329,537 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL 3 results improve the commercial and regulatory outlook for BridgeBio’s achondroplasia program — a fundamental driver for longer‑term upside. PROPEL 3 Results
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and boosted its price target to $100 while maintaining a Buy — analyst upgrades can support buying interest and help re‑rate shares if fundamentals continue to improve. HC Wainwright PT Raise
• Positive Sentiment: Broad analyst coverage remains constructive (multiple Buy/Overweight ratings and higher targets), which can amplify rallies following positive clinical/financial news. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results and host a Feb. 24 conference call — this is the next near‑term catalyst that could drive volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to new hires (~76,701 shares aggregate) — modest ongoing share‑based comp that could be a small dilution factor to monitor. Inducement Grants
• Neutral Sentiment: Oppenheimer reported a small new 13F position (~7,845 shares) — modest institutional interest but not yet material to the register. Oppenheimer 13F
• Neutral Sentiment: Short‑interest reporting for Feb. 19 shows anomalous/zero values in the feed (likely a data/reporting glitch) — no clear evidence of a meaningful short squeeze or build from this item alone.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal W. Scott sold 10,000 shares and senior officers (CFO and CAO) also disclosed sales (CFO ~13,600 shares; CAO 510 shares) — concentrated insider disposals are weighing on near‑term sentiment. Insider Trades
• Negative Sentiment: Ongoing pattern of executive liquidity events highlighted in reporting — repeated insider selling can keep downward pressure on the stock until insiders demonstrate renewed accumulation. Insider/Sentiment Summary

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.